Immix Biopharma, Inc. (IMMX) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
2.85
↓-17% vs avg
5yr avg: 3.42
30Y Low0.7·High7.4
ROE
↑
-55.0%
↓+62% vs avg
5yr avg: -145.5%
30Y Low-368%·High-53%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMMX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immix Biopharma, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $441M | $172M | $62M | $120M | $32M | $13M | — | — |
| Enterprise Value | $348M | $80M | $46M | $102M | $18M | $-4519983 | — | — |
| P/E Ratio → | -9.10 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | 2.85 | 1.84 | 4.70 | 7.41 | 2.42 | 0.73 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMMX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
IMMX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -55.0% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -55.0% | -55.0% | -146.8% | -105.1% | -52.8% | -367.8% | — | — |
| ROA | -46.1% | -46.1% | -100.8% | -88.6% | -49.7% | -260.3% | -154.9% | -103.2% |
| ROIC | -2169.8% | -2169.8% | — | — | -10389.5% | -256.3% | — | — |
| ROCE | -49.9% | -49.9% | -148.9% | -108.2% | -52.0% | -20.4% | — | — |
IMMX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $94M exceeds total debt of $1M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.08 | — | — | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.99 | -1.25 | -1.08 | -1.02 | -0.98 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -16537.12 | -134.54 | -4.45 | -7.66 |
Net cash position: cash ($94M) exceeds total debt ($1M)
IMMX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Immix Biopharma, Inc.'s current ratio of 10.01x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.32x to 10.01x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.01 | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Quick Ratio | 10.01 | 10.01 | 2.33 | 5.32 | 11.70 | 90.01 | 0.10 | 0.20 |
| Cash Ratio | 9.93 | 9.93 | 2.04 | 4.70 | 10.55 | 87.33 | 0.07 | 0.16 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
IMMX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immix Biopharma, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.0% | — | — |
| Shares Outstanding | — | $33M | $28M | $17M | $14M | $4M | $8M | $3M |
Peer Comparison
Compare IMMX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMMXYou | $441M | -9.1 | — | — | — | — | -55.0% | -2169.8% | — |
 CABA | $491M | -1.8 | — | — | — | — | -127.0% | -429.6% | — |
 KYMR | $7B | -22.5 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 IMVT | $7B | -11.9 | — | — | — | — | -64.8% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 FATE | $230M | -1.7 | — | — | -94.1% | -2222.4% | -51.8% | -36.5% | — |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 EDIT | $239M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -7.8 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
What if you invested $1,000 in IMMX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IMMX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMMX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMMX vs CABA — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Cabaletta Bio, Inc..
Compare NowIMMX — Frequently Asked Questions
Quick answers to the most common questions about buying IMMX stock.
What is Immix Biopharma, Inc.'s P/E ratio?
Immix Biopharma, Inc.'s current P/E ratio is -9.1x. This places it at the 50th percentile of its historical range.
What is Immix Biopharma, Inc.'s ROE?
Immix Biopharma, Inc.'s return on equity (ROE) is -55.0%. The historical average is -145.5%.
Is IMMX stock overvalued?
Based on historical data, Immix Biopharma, Inc. is trading at a P/E of -9.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.